Fluid homeostatic action of dapagliflozin in patients with chronic kidney disease: the DAPA-BODY TrialKentaro Oka, Daisuke Nagata, Yasuharu Miyazawa et al.|Frontiers in Medicine|2023Cited by 16
Sodium–Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume ReductionMaki Asakura-Kinoshita, Daisuke Nagata, Takahiro Masuda et al.|Diagnostics|2024Cited by 14
SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: the DAPA-BODY trialTakahiro Masuda, Yoshiyuki Morishita, Daisuke Nagata et al.|Hypertension Research|2025Cited by 5